SPARC196.80

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health
₹ CrorePeersSTARSHILPAMEDSUPRIYATHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹6,386 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×1.001.001.001.00
Interest Burden (Pretax/EBIT) ×0.931.020.980.99
EBIT Margin %-548.79-467.5184.5384.17
Asset Turnover ×0.150.210.870.87
Financial Leverage (Assets/Equity) ×4.10-1.551.621.62
ROE (5-step product) %-314.87155.00116.60117.05
ROE (reported, avg-equity basis) %-307.92157.96116.20116.20
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.